Abstract: A mirror, a mirror substrate, a method for producing are provided. The mirror substrate is made of a material having a coefficient of mean linear thermal expansion of less than or equal to 1*10?6/K. The mirror substrate includes at least one feature selected from a group consisting of: a ratio of a lateral dimension to a maximum thickness of at least 100, a ratio of the lateral dimension to the maximum thickness of at least 150, a ratio of the lateral dimension to the maximum thickness of at least 200, a ratio of the lateral dimension to the maximum thickness of at least 300, a weight per unit area of 100 kg/m2 or less, a weight per unit area of 50 kg/m2 or less, a weight per unit area of 30 kg/m2 or less, a weight per unit area of 15 kg/m2 or less, a mirror surface with a roughness (Ra) of at most 3.5 ?m, and a mirror surface with a roughness (Ra) of less than 1.2 ?m.

Abstract: A mirror substrate is made of a material having a coefficient of mean linear thermal expansion of less than or equal to 1*10?6/K. The mirror substrate includes at least one of: a ratio of a lateral dimension to a maximum thickness of at least 100,, a weight per unit area of 100 kg/m2 or less,, and a mirror surface with a roughness (Ra) of at most 3.5 ?m.

Abstract: The present invention relates to a compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof, wherein Y3 is O or S, wherein s, t, u and w are, independently of each other, 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are independently of each other, selected from the group consisting of CO2H, —SO2H, —SO3H, —OSO3H, and —OPO3H2, R1 is —CH3 or H, preferably H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y1 and Y2 are independently, of each other, selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (Ia), (Ib) and (Ic) wherein R2, R3, R4 and R5 are, independently of each other, selected from the group consisting of H, —CH2—COOH and —CH2—C(?O)—NH2 or wherein R2 and R4 form a —(CH2)n— bridge with n being an integer

Abstract: A rotary pressure filter, comprising a filter drum and a housing. A sensor is attached to the housing and emits light through a light-permeable section of the housing in the direction of a filter cake. The sensor receives light reflected from the filter cake through the light-permeable section of the housing. A processing unit compares properties of the emitted light with those of the received light and determines an absolute thickness of the filter cake and/or a change in the thickness of the filter cake over a pre-determined time. The invention further relates to a corresponding method.

Abstract: A nickel-base alloy for high-temperature applications, preferably for gas turbines, and a process. A selective choice of alloy elements permits the provision of an alloy which can be used to produce components devoid of cracking.

Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: A compound or a pharmaceutically acceptable salt thereof of formula (I): (A)-x1-(B)-x2-(C), wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x1 is a spacer covalently connecting (A) and (B); x2 is a spacer or a chemical single bond connecting (B) and (C); wherein (C) has the formula wherein R1 to R4, R9, a, b, Y and X1 to X4 have the meaning as indicated in the claims and description. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present disclosure relates to a vehicle steering wheel, including: a steering wheel body with a hub region for attachment to a steering shaft, with a steering wheel rim and with at least one spoke for attaching the steering wheel rim to the hub region; an airbag initiation device; wherein an electromechanical triggering device has at least one force transducer, which is disposed between a projection and the steering wheel body and via which the impact absorber cover is supported on the steering wheel body, for measuring a force value that can be associated with an actuating force acting on the actuating surface of the impact absorber cover; wherein the electromechanical triggering device has at least one electronic evaluation unit connected in an electrically conductive manner to the force transducer to determine an actuating force value by a force value measured by the at least one force transducer.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

Abstract: A device includes a first supply unit, which is connectable via a first switch element to a first consumer, a second supply unit, which is connectable via a second switch element and via one or more electric delimitation elements to the first consumer, and a third switch element, which is configured to bridge the one or more electric delimitation elements. A control unit is configured to cause the first switch element to close, and the second and third switch elements to open, in normal operation. The control unit is further configured to detect that a first supply voltage at the first supply unit has reached or fallen below a voltage threshold value, and in response causes first the second switch element to close, then the first switch element to open, and then the third switch element to close, such that the first consumer is coupled to the second supply unit.

Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , t ? i ? s ? s ? u ? e = C t ? mAb , tissue , det . C tissue , sample - C refmAb , tissue , det . C tissue , sample C refmAb , plasma , det . * C tmAb , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.

Abstract: A system includes a core drill and an automatic feed device. The core drill has a human machine interface (HMI) for controlling the core drill and the automatic feed device. A menu navigation of the HMI is automatically controllable in dependence on an operating state of the core drill or the automatic feed device. The menu navigation includes menu pages where the menu pages are displayable in dependence on the operating state of the core drill or the automatic feed device such that the menu navigation is controllable automatically depending on the operating state of the core drill or the automatic feed device.

Abstract: An electrical connector includes: at least a first housing part and a second housing part, an engagement region of one of the first housing part and the second housing part engaging at least partially and concentrically with an other of the first housing part and the second housing part, the first housing part and the second housing part being rotatable in the engagement region relative to each other about an axis of rotation; at least one bolt disposed in the engagement region, which in a first basic state secures the first housing part and the second housing part against rotation of the housing parts relative to each other about the axis of rotation, and in a second basic state releases the housing parts. The at least one bolt is magnetic and preloaded by a spring force.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Abstract: An electrical connector includes: at least a first housing part and a second housing part, one of the first housing part and the second housing part engaging, at least partially and concentrically, in an other of the first housing part and the second housing part in an engagement region, the first housing part and the second housing part being rotatable relative to one another in the engagement region about an axis of rotation. The first housing part and the second housing part each have a magnetic structure extending, at least in part, circumferentially on an inside or an outside in the engagement region, the respective magnetic structures interacting.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.